BioVie announces Phase 2 Alzheimer's results for NE3107 with cognitive and biomarker improvements

BIOVIE INC.

82% of 17 mild AD patients showed 2.6-point decrease in ADAS-Cog12 (p=0.046) after 3 months of NE3107.
NE3107 significantly reduced TNF-alpha; improvements in cognition correlated with TNF reduction (R=0.70, p=0.0077).
Phase 3 AD trial (NCT04669028) half enrolled; topline data expected mid-2023, subject to DSMB review.
Phase 2 Parkinson's trial (NCT05083260) enrolling; data readout by end of 2022; early efficacy signal detected.
Phase 2b BIV201 trial for ascites delayed by COVID; data readout anticipated mid-2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.